A cure for the high cost of hepatitis C virus treatment

doi:10.7326/M15-0674

Editorial

. 2015 May 5;162(9):660-1.

doi: 10.7326/M15-0674.

A cure for the high cost of hepatitis C virus treatment

Ohad Etzion, Marc G Ghany

PMID: 25820765
PMCID: PMC7460276
DOI: 10.7326/M15-0674

Editorial

A cure for the high cost of hepatitis C virus treatment

Ohad Etzion et al. Ann Intern Med. 2015.

. 2015 May 5;162(9):660-1.

doi: 10.7326/M15-0674.

Authors

Ohad Etzion, Marc G Ghany

PMID: 25820765
PMCID: PMC7460276
DOI: 10.7326/M15-0674

No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M15-0674.

Comment on

The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.
Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Freedberg KA, Kim AY. Linas BP, et al. Ann Intern Med. 2015 May 5;162(9):619-29. doi: 10.7326/M14-1313. Ann Intern Med. 2015. PMID: 25820703 Free PMC article.

Cited by

Marmosets as models of infectious diseases.
Herron ICT, Laws TR, Nelson M. Herron ICT, et al. Front Cell Infect Microbiol. 2024 Feb 23;14:1340017. doi: 10.3389/fcimb.2024.1340017. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38465237 Free PMC article. Review.
Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study.
Etzion O, Dahari H, Yardeni D, Issachar A, Nevo-Shor A, Cohen-Naftaly M, Ashur Y, Uprichard SL, Arbib OS, Munteanu D, Braun M, Cotler SJ, Abufreha N, Keren-Naus A, Shemer-Avni Y, Mor O, Murad J, Novack V, Shlomai A. Etzion O, et al. Sci Rep. 2020 Oct 20;10(1):17820. doi: 10.1038/s41598-020-74568-x. Sci Rep. 2020. PMID: 33082372 Free PMC article.
Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.
Chidi AP, Bryce CL, Donohue JM, Fine MJ, Landsittel DP, Myaskovsky L, Rogal SS, Switzer GE, Tsung A, Smith KJ. Chidi AP, et al. Value Health. 2016 Jun;19(4):326-34. doi: 10.1016/j.jval.2016.01.010. Epub 2016 Mar 24. Value Health. 2016. PMID: 27325324 Free PMC article.
Criteria for Drug Pricing: Preliminary Experiences with Modeling the Price-Volume Relationship.
Messori A. Messori A. Sci Pharm. 2015 Aug 27;84(1):73-9. doi: 10.3797/scipharm.1506-03. Print 2016 Jan-Mar. Sci Pharm. 2015. PMID: 27110499 Free PMC article.
Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation.
Cenderello G, Artioli S, Viscoli C, Pasa A, Giacomini M, Giannini B, Dentone C, Nicolini LA, Cassola G, Di Biagio A. Cenderello G, et al. Clinicoecon Outcomes Res. 2015 Dec 31;8:15-21. doi: 10.2147/CEOR.S93641. eCollection 2016. Clinicoecon Outcomes Res. 2015. PMID: 26770065 Free PMC article.

References

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128. doi:10.1016/S0140-6736(12)61728-0 - DOI - PMC - PubMed
1. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–93. doi:10.1001/jama.2012.144878 - DOI - PubMed
1. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368:1859–61. doi:10.1056/NEJMp1302973 - DOI - PMC - PubMed
1. Liang TJ, Ghany MG. Therapy of hepatitis C—back to the future [Editorial]. N Engl J Med. 2014;370:2043–7. doi: 10.1056/NEJMe1403619 - DOI - PMC - PubMed
1. Sofosbuvir (Sovaldi) for chronic hepatitis C. Med Lett Drugs Ther. 2014;56:5–6. - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

Z01 DK075009/ImNIH/Intramural NIH HHS/United States

LinkOut - more resources

Full Text Sources

[1] Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128. doi:10.1016/S0140-6736(12)61728-0 - DOI - PMC - PubMed

[2] Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128. doi:10.1016/S0140-6736(12)61728-0 - DOI - PMC - PubMed

[3] van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–93. doi:10.1001/jama.2012.144878 - DOI - PubMed

[4] van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–93. doi:10.1001/jama.2012.144878 - DOI - PubMed

[5] Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368:1859–61. doi:10.1056/NEJMp1302973 - DOI - PMC - PubMed

[6] Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368:1859–61. doi:10.1056/NEJMp1302973 - DOI - PMC - PubMed

[7] Liang TJ, Ghany MG. Therapy of hepatitis C—back to the future [Editorial]. N Engl J Med. 2014;370:2043–7. doi: 10.1056/NEJMe1403619 - DOI - PMC - PubMed

[8] Liang TJ, Ghany MG. Therapy of hepatitis C—back to the future [Editorial]. N Engl J Med. 2014;370:2043–7. doi: 10.1056/NEJMe1403619 - DOI - PMC - PubMed

[9] Sofosbuvir (Sovaldi) for chronic hepatitis C. Med Lett Drugs Ther. 2014;56:5–6. - PubMed

[10] Sofosbuvir (Sovaldi) for chronic hepatitis C. Med Lett Drugs Ther. 2014;56:5–6. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A cure for the high cost of hepatitis C virus treatment

A cure for the high cost of hepatitis C virus treatment

Authors

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources